Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Nodular regenerative hyperplasia of the liver is a rare parenchymatous liver disease characterized by diffuse benign transformation of the hepatic parenchyma into multiple small nodules (composed of regenerating hepatocytes) and that is usually asymptomatic but can lead to the development of non-cirrhotic portal hypertension and its complications, including esophageal variceal bleeding, hypersplenism and ascites. It is often associated with rheumatologic, autoimmune, hematologic, and myeloproliferative disorders as well as various immune deficiency states and exposure certain drugs and toxins.
Features include very common findings: Abnormality of the hepatic vasculature; and sometimes findings: Portal hypertension.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Heart and blood vessels | 2 | Portal hypertension, Abnormality of the hepatic vasculature |
Biomarker and diagnostic research for nodular regenerative hyperplasia of the liver has been reported in the published literature.
Phenotype severity distribution: 1 very common feature.
Estimated prevalence: Unknown (Unknown prevalence).
7 clinical trials registered, 5 recruiting. Interventions under study include other interventions, medical devices, and procedural interventions. Pipeline includes 1 NA. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06500403](https://clinicaltrials.gov/study/NCT06500403) |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 9:10 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
1 |
Abnormality of the hepatic vasculature |
Non-invasive Tools for PSVD Diagnosis
— |
Nanfang Hospital, Southern Medical University |
RECRUITING |
[NCT06054451](https://clinicaltrials.gov/study/NCT06054451) | Clinical Diagnosis and Pathological Spectrum of Porto-sinusoidal Vascular Disease in India | — | Post Graduate Institute of Medical Education and Research, Chandigarh | UNKNOWN |
[NCT07424963](https://clinicaltrials.gov/study/NCT07424963) | Hepatic Venous Pressure Gradient Versus Endoscopic Ultrasound-Guided Portal Pressure Gradient - Comparative Analysis (HEPCA) | NA | Military University Hospital, Prague | RECRUITING |
[NCT02417740](https://clinicaltrials.gov/study/NCT02417740) | Natural History of Noncirrhotic Portal Hypertension | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | RECRUITING |
[NCT05782556](https://clinicaltrials.gov/study/NCT05782556) | Freiburg TIPS Registry | — | University Hospital Freiburg | RECRUITING |
82 publications have been identified in PubMed for nodular regenerative hyperplasia of the liver. Research spans Review / Meta-Analysis (28%), Case Report / Case Series (26%), and Epidemiology / Natural History (17%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 23 | 28% |
Patient case studies | 21 | 26% |
Disease patterns and progression | 14 | 17% |
Testing and diagnosis research | 13 | 16% |
Laboratory research | 7 | 9% |
Other research | 3 | 4% |
Clinical study results | 1 | 1% |
Pirzada SA (2026). [PMID: 42215326](https://pubmed.ncbi.nlm.nih.gov/42215326/). *Semin Hematol*. [Review / Meta-Analysis]
Corvilain E (2026). [PMID: 41762359](https://pubmed.ncbi.nlm.nih.gov/41762359/). *J Clin Immunol*. [Epidemiology / Natural History]
Shimamoto T (2026). [PMID: 42149326](https://pubmed.ncbi.nlm.nih.gov/42149326/). *Clin J Gastroenterol*. [Case Report / Case Series]
Chen L (2026). [PMID: 42118005](https://pubmed.ncbi.nlm.nih.gov/42118005/). *Expert Opin Drug Saf*. [Review / Meta-Analysis]
Merk J (2026). [PMID: 41406992](https://pubmed.ncbi.nlm.nih.gov/41406992/). *Pediatrics*. [Case Report / Case Series]
de Broucker C (2026). [PMID: 41492317](https://pubmed.ncbi.nlm.nih.gov/41492317/). *JHEP Rep*. [Case Report / Case Series]
Singh A (2026). [PMID: 42022180](https://pubmed.ncbi.nlm.nih.gov/42022180/). *J Clin Exp Hepatol*. [Case Report / Case Series]
Gong W (2026). [PMID: 41849926](https://pubmed.ncbi.nlm.nih.gov/41849926/). *Clin Radiol*. [Diagnostic / Biomarker]
Candi J (2026). [PMID: 41468954](https://pubmed.ncbi.nlm.nih.gov/41468954/). *Clin Res Hepatol Gastroenterol*. [Other]
Aleyadeh W (2026). [PMID: 41713550](https://pubmed.ncbi.nlm.nih.gov/41713550/). *J Allergy Clin Immunol Pract*. [Diagnostic / Biomarker]